Bank of New York Mellon Corp Acquires New Shares in Savara Inc. $SVRA

Key Points

• Bank of New York Mellon acquired 372,367 Savara shares worth approximately $2.3 million, while institutional ownership reached 87.93%. Other major investors, including Polar Capital and RTW Investments, also established or expanded positions.
• Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and a $10.14 price target. However, Weiss Ratings and Wall Street Zen issued sell-related assessments.
• Savara reported a quarterly loss of $0.16 per share, missing estimates by $0.02. The clinical-stage biopharmaceutical company is developing Molgradex for autoimmune pulmonary alveolar proteinosis.

Bank of New York Mellon Corp acquired a new position in Savara Inc. (NASDAQ:SVRA - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 372,367 shares of the company's stock, valued at approximately $2,294,000. Bank of New York Mellon Corp owned 0.18% of Savara at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SVRA. Polar Capital Holdings Plc bought a new stake in shares of Savara in the 4th quarter valued at about $50,086,000. RTW Investments LP bought a new position in Savara in the fourth quarter worth approximately $35,893,000. VR Adviser LLC lifted its holdings in Savara by 172.7% during the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company's stock worth $20,256,000 after buying an additional 5,626,624 shares during the period. Marshall Wace LLP purchased a new stake in Savara during the fourth quarter worth $27,496,000. Finally, Spruce Street Capital LP bought a new stake in Savara during the 4th quarter valued at $14,539,000. 87.93% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on SVRA shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. Wall Street Zen lowered shares of Savara from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.14.

Savara Stock Performance

Savara stock opened at $5.37 on Tuesday. The stock has a 50-day moving average of $5.64 and a two-hundred day moving average of $5.47. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. Savara Inc. has a one year low of $3.34 and a one year high of $7.01. The stock has a market cap of $1.10 billion, a PE ratio of -9.26 and a beta of 0.25.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). On average, research analysts anticipate that Savara Inc. will post -0.62 EPS for the current fiscal year.

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.